Fly News Breaks for December 19, 2017
Dec 19, 2017 | 06:59 EDT
After evaluating the company's strategic options, including the sale of its U.K. business, monetizing its real estate, and a leveraged buyout, Jefferies analyst Brian Tanquilut believes "meaningful value" could be realized in Acadia Healthcare, even absent any near-term improvement in fundamentals. A divestiture of the U.K. business or a sale-leaseback could push Acadia shares to $46, Tanquilut tells investors in a research note. In a leveraged buyout, Acadia should command greater than $48 per share, the analyst contends. He views the company as a viable LBO candidate and keeps a Buy rating on the shares with a $42 price target.
News For ACHC From the Last 2 Days
Nov 19, 2018 | 07:20 EDT
Leerink analyst Ana Gupte views Acadia (ACHC) as being oversold after the CNBC newsflow on Friday around the issues ongoing with the sale process to KKR (KKR). The analyst notes that it is unclear to her if the strategic leak to CNBC is coming from the company itself to signal the end of the current sale process, or is a move from the current potential buyers in pursuit of a lower price. Gupte reiterates a Market Perform rating and $42 price target on Acadia shares.